Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: A review

Clinical Interventions in Aging

Volumn 4, Issue 1, 2009, Pages 59-62

  Carranza Lira, Sebastián ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

Drospirenone; Estradiol; Postmenopause; Review

Indexed keywords

DROSPIRENONE; ESTRADIOL; MEDROXYPROGESTERONE; NORETHISTERONE; PLACEBO;

ABDOMINAL PAIN; BLOOD CLOTTING; BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIAL DISEASE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; HORMONAL THERAPY; HOT FLUSH; HUMAN; INSOMNIA; MASTALGIA; MENOPAUSAL SYNDROME; MONOTHERAPY; NERVOUSNESS; POLYP; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SPOTTING; SWEATING; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX POLYP; VAGINA BLEEDING; VAGINAL DRYNESS; VASOMOTOR DISORDER; WEIGHT GAIN;

AGED; ALDOSTERONE ANTAGONISTS; ANDROSTENES; BLOOD PRESSURE; BODY WEIGHT; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; LIPOPROTEINS; MENOPAUSE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUALITY OF LIFE; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

EID: 66249143021     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Carranza-Lira S. Actualidades en terapia hormonal. Universum-Mexico. 2008.
2. Carranza-Lira S, Cortés-Fuentes E. Modification of vasomotor symptoms after different treatment modalities in the postmenopause. Int J Gynaecol Obstet. 2001;73(2):169-171.
3. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril. 2001;756(6):1065-1079.
4. Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
5. Harman SM. Estrogen replacement in menopausal women: Recent and current prospective studies, the WHI and the KEEPS. Gend Med. 2006;3(4):254-269.
6. Figueroa-Casas PR, Ettinger B, Delgado E, Javkin A, Vieder C. Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy. Menopause. 2001;8(6):420-423.
7. Lobo RA. Absorption and metabolic effects of different types of estrogen and progestogens. Obstet Gynecol Clin North Am. 1987; 14(1):143-167.
8. Jackson VP, San Martin JA, Secrest RJ, et al. Comparison of the effect of raloxifene and continuous combined hormone replacement therapy on mammographic breast density and breast tenderness in postmenopausal women. Am J Obstet Gynecol. 2003;188(2):389-394.
9. Genazzani AR, Mannella P, Simoncini T. Drospirenone and its antial-dosterone properties. Climacteric. 2007;10 Suppl 1:11-18.
10. Sitruk-Ware R. Pharmacology of different progestogens: the special case of drospirenone. Climacteric. 2005;8 Suppl 3:4-12.
11. Ylikorkala O. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Climacteric. 2005;8 Suppl 3:1-3.
12. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralocorticoid activity. Arzeneimuttelforschung. 1985;35(2):459-471.
13. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab. 1991;73(4):837-842.
14. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004;217(1-2):255-261.
15. Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric. 2007;10 Suppl 1:3-10.
16. Schürmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric. 2004;7(2):189-196.
17. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause. 2005;16(6):716-727.
18. Lee BS, Kang BM, Yoon BK, Choi H, Park HM, Kim JG. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: A double-blind, randomized, placebo-controlled, multicenter study. Maturitas. 2007;57(4):361-369.
19. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17 beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation. 2005;112(13):1979-1984.
20. White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension. 2006;48(2):243-253.
21. Mallareddy M, Hanes V, White WB. Drospirenone, a new progestogen, for postmenopausal women with hypertension. Drugs Aging. 2007;24(6):453-466.
22. Panay N, Studd J. Progestogen intolerance and compliance with hormone replacement therapy in menopausal women. Hum Reprod Update. 1977;3(2):159-171.
23. Sherwin BB, Gelfand MM. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids. Obstet Gynecol. 1989;73(5 pt 1):759-766.
24. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2004;47(4):277-283.